FINDING ACCEPTABLE WAYS TO FUND RESEARCH ON E-CIGARETTES
The US tobacco industry's egregious misrepresentation of scientific evidence on the harms of smoking is well documented in The Cigarette Papers [1] and histories of tobacco use [2, 3] . It explains why the suggestion that researchers should take funds from Big Tobacco is anathema, and ensures that researchers who take tobacco industry funding are ostracized by their (former) colleagues.
This seems to have been the experience of John Hughes and colleagues [4] , despite their distinguished records of research on the harms of tobacco cigarettes and Dr Henningfield giving evidence against the tobacco industry in plaintiff litigation. Their letter offers a justification of their decision to take funding from the industry in order to undertake research solely on reduced risk nicotine and tobacco products, including e-cigarettes.
Hughes et al. summarize the strong public health case for investigating tobacco harm reduction (THR) products. Tobacco control policies have massively discouraged smoking by raising taxes and smoke-free policies have very substantially reduced smoking prevalence, but a minority of smokers are unable or unwilling to quit. Modelling suggests that THR products have the potential to dramatically reduce tobacco-related harm without undermining the goal of eliminating the combustible cigarette [5] .
I accept that there is a strong case for funding research on THR but I doubt, given US history, that oversight by the Food and Drug Administration (FDA) will be enough to ensure that the industry behaves in an ethical way. Nor do I believe that successful FDA oversight would be enough to convince public health critics of tobacco harm reduction that their research findings could be trusted.
The pharmaceutical industry solution of untied grants to fund investigations of reduced risk products-such as the funding for Professor Rodu-is also unlikely to convince sceptics. The hostility to the Phillip Morris International Smoke Free World Initiative (e.g. [6, 7] ) suggests that no industry funding is acceptable, even if Phillip Morris honoured its promise to allow these funds to be allocated at arms-length.
I would favour an alternative funding approach, namely a hypothecated tax on e-cigarettes and tobacco products [8] to fund peer-reviewed research on tobacco harm reduction. The quality and design of the research would be assessed by independent peer reviewers and the process managed by funding bodies, such as the National Institutes of Health or the FDA. By this process research could be funded on the effectiveness and safety of popular brands of e-cigarettes for smoking cessation and as long-term replacements for cigarettes. It could also assess the extent of e-cigarette uptake among non-smokers and design and evaluate policies that would minimize such uptake.
Funds from a hypothecated tax allocated in this way would eliminate any tobacco industry involvement in the research. It would also flush out those in the tobacco control community whose opposition to tobacco harm reduction is based on moral grounds, rather than on reasonable concerns about adverse public health impacts that are open to empirical test [9] .
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WHY SOME RESEARCHERS CHOOSE NOT TO WORK WITH THE TOBACCO INDUSTRY
In this issue of Addiction, Hughes and colleagues provide an outline of the reasons they accept tobacco industry funding [1] . They express confidence in regulatory agencies in ensuring accountability and transparency and highlight the need to use all resources available, even from the tobacco industry itself, for finding a solution to the global public health disaster that is tobacco smoking.
As Hughes et al. point out, tobacco companies seeking to make money from reduced harm products is not, in itself, a menace to public health, but tampering with research results or policy to ensure a product appears more effective and safe than it may be is a problem. Internationally, there are widespread agreements regarding the use of tobacco industry funds in research. Both the UN General Assembly and the World Health Organization (WHO) have warned of significant conflict of interest between the tobacco industry and public health [2, 3] , and there is good reason for this position. The tobacco industry has been found to interfere with health science using a variety of methods such as suppressing unfavourable results and funding 'distraction' research on causes of disease other than smoking [4, 5] . Industry interference can also extend beyond research and into science policy development. It is disconcerting that in an examination of the recent Brussels Declaration on Ethics and Principles for Science and Society Policy-making, the tobacco industry was singled out as a major player building industry coalitions to attempt to influence science policy in their favour [6] .
Despite the risks involved in industry funding of health research, many national and international research organizations acknowledge that engagement with industry is important. In some countries, funding partnerships are encouraged to increase the likelihood that the research is translated by end-users and the community benefits from the research, but how do researchers engage with industry and avoid or minimize interference or bias? In these instances, full disclosure of interests are an important requirement for journals and scientific meetings [7, 8] . However, more is required to safeguard the independence and integrity of health research and researchers. Bauld
